Progress towards achieving and maintaining maternal and neonatal tetanus elimination in the African region

Progress towards achieving and maintaining maternal and neonatal tetanus elimination in the African Region

Alison Delano Ridpath^1,&, Heather Melissa Scobie¹, Messeret Eshetu Shibeshi², Ahmadu Yakubu³, Flint Zulu⁴, Azhar Abid Raza⁴, Balcha Masresha², RaniaTohme¹

 

¹Centers for Disease Control and Prevention, Global Immunization Division, Atlanta, GA, USA, ²World Health Organization, Intercountry Support Team for East and Southern Africa, Harare, Zimbabwe, ³World Health Organization,Family, Women and Children’s Health Cluster, Geneva, Switzerland, ⁴United Nations Children’s Fund, Health Section, Program Division, New York, NY, USA

 

 

^&Corresponding author
Alison Delano Ridpath, Centers for Disease Control and Prevention, Global Immunization Division, Atlanta, GA, USA

 

 

 

 

Tetanus is a non-communicable vaccine-preventable disease caused by the bacterium Clostridium tetani (C. tetani). The disease cannot be eradicated because C. tetani spores exist in the environment [1]. Although tetanus can occur in all age-groups, neonates and women with recent pregnancies are most at risk, particularly when childbirths(or terminations of pregnancies) take place under unhygienic conditions [2]. Neonatal tetanus (NT) occurs during the first 28 days of life and maternal tetanus occurs during or within the first 6 weeks after pregnancy. Case-fatality rates from tetanus in resource-limited settings can be up to 100%, though with adequate medical care rates can be reduced to 10-20% [3].

 

Tetanus toxoid containing vaccine (TTCV) is one of the most effective, safe, heat-stable, and inexpensive vaccines ever developed [4]. TTCV can be given safely during pregnancy to protect both mothers and newborns [5]. Vaccines containing tetanus for infants and pregnant women have been part of the WHO Expanded Program on Immunizations since its inception. WHO recommends a 6 dose schedule of TTCV including 3 doses in infancy and 3 booster doses, 1 each during the second year of life, childhood (4–7 years), and adolescence (9-15 years), to provide long-term protection against tetanus in all ages [3]. For previously non-immunized adolescents and adults, a total of 5 TTCV doses are recommended [3]. In countries where maternal and neonatal tetanus (MNT) is still a problem, pregnant women whose tetanus vaccination history is unknown or inadequate are recommended to receive 2 TTCV doses during their first pregnancy, with the first dose provided at first contact with health services and the second dose provided at least 4 weeks later and at least 2 weeks before delivery [3]. The third dose can be given at least 6 months after the second, and 2 boosters are provided during subsequent pregnancies or at least 1 year later. This schedule has been shown to reduce neonatal mortality from tetanus by 94% [5].

 

In industrialized countries, MNT was generally eliminated before vaccine introduction through clean birth practices [6]. Deliveries assisted by skilled birth attendants (SBA), who can ensure clean delivery practices and education on hygienic umbilical cord practices, has been shown to be an effective intervention to prevent MNT and to reduce neonatal mortality due to tetanus by 50–70% [6-9].

 

In 1988, NT was estimated to cause over 787,000 deaths per year [10]. To address the global burden of NT, in 1989, The World Health Assembly called for the elimination of NT by 1995, defined as an incidence of <1 NT case per 1,000 live births in every district annually [11]. Maternal tetanus elimination was added in 1999, and the goal was relaunched through a partnership with World Health Organization (WHO), United Nations Children’s Fund (UNICEF), and United Nations Population Fund (UNFPA) as the Maternal and Neonatal Tetanus Elimination (MNTE) Initiative, focusing on 59 priority countries (including the addition of Timor Leste and South Sudan) that had not yet achieved elimination as of 2000 [7, 12]. The strategies recommended by the UN agency partnership to achieve MNTE are 1)routine immunization of women during pregnancy with TTCV, 2) immunization of all women of reproductive age (WRA) living in high risk areas with 3 doses of TTCV, 3) delivery by SBA to ensure clean delivery practices, and4) surveillance for NT cases [7]. High-risk districts for MNT are defined as those reporting clean delivery coverage of < 70% and coverage with at least 2 TTCV doses <80% during the past 5 years among pregnant women or WRA [12]. All WRA living in high-risk areas are provided 3 doses of TTCV irrespective of their previous vaccination status, through appropriately spaced supplementary immunization activity (SIA) rounds [12]. As a result of MNTE efforts, the estimated number of NT deaths has been reduced by 94% (49,000 estimated deaths) in 2013, compared to 1988 [13]. However, the target date for MNTE has been repeatedly missed and extended; the most recent target date was 2015 [7]. As of October 2016, 41(69%) of the 59 priority countries identified have achieved MNTE [14].

 

Beyond MNTE, a goal of tetanus vaccination is to prevent tetanus in all ages [3].The Global Vaccine Action Plan (GVAP) set a target of 90% coverage with three doses of diphtheria, tetanus, and pertussis containing vaccine (DTP3/Penta) among children aged <12 months nationally, and 80% in every district by 2015 [15]. GVAP objectives also emphasize equitable provision of vaccines to underserved areas and marginalized groups, as well as introducing strategies to provide vaccinations to all ages (“life course approach”). High vaccination coverage and provision of tetanus booster doses throughout the lifespan would raise population immunity and sustain achievements of the MNTE Initiative.

 

The World Health Organization (WHO) African Region (AFR) consists of 47 countries in Sub-Saharan Africa that carry a substantial burden of the remaining MNT cases. In this paper, we describe the current status of progress towards MNTE in AFR, discuss the challenges and barriers to reaching elimination, and make recommendations for reaching and maintaining elimination in the region.

 

 

For each country in AFR, we reviewed national vaccination schedules, vaccination coverage estimates and reported NT cases from the WHO-UNICEF joint reporting form available on the WHO website [16-21]. WHO-UNICEF coverage estimates were reviewed to determine coverage of the third dose of Diphtheria Tetanus and Pertussis vaccine (DTP3)/Pentavalent vaccine (Penta 3) among children aged <12 months and the proportion of births in a given year that can be considered as having been protected against tetanus (protected at birth, PAB) as a result of maternal immunization [19, 20]. WHO-UNICEF estimates of PAB were calculated on the basis of mathematical modeling [22], whereas PAB is usually defined as having received 2 tetanus toxoid (TT) doses during the last birth, ≥2 TT doses with the last dose ≥ 3 years prior to the last birth, ≥3 doses with the last dose ≤ 5 years prior, ≥4 doses with the last dose ≤10 years prior, or ≥ 5 prior doses [23]. Official country administrative coverage figures reported to WHO-UNICEF were reviewed for the proportion of women who have received their second or subsequent dose of TTCV during pregnancy (TT2+) [21]. Administrative TT2+ coverage is calculated by dividing the number of pregnant women who received the second or subsequent dose of TT by the estimated number of live births for the year [24]. 2005, 2010, and 2011-2015 averages forDTP3/Penta3, TT2+, and PAB coverage were calculated for countries yet to achieve MNTE and those that have achieved MNTE using the formula: (sum of (coverage x target population)) / sum of target populations). NT incidence rates were calculated for each country based on the number of reported cases divided by the number of births. Population denominators are from the United Nations Population Division [25].

 

The number of WRA (generally 15–49 years of age) targeted and reached with TT2+ by SIAs for each country yet to achieve elimination were reviewed from the WHO data on MNTE SIAs [26]. The proportion of deliveries attended by a SBA as reported to UNICEF were reviewed for each country in the region [27]. We searched PubMed and the WHO website for relevant articles and reports relating to MNTE globally or within AFR published up to September 1, 2016 [28]. Additionally, we reviewed presentations and reports from the Strategic Advisory Group of Experts Working Group on Maternal and Neonatal Tetanus Elimination and Broader Tetanus Prevention [29].

 

 

Current status of MNTE Initiative in AFR

 

When the MNTE Initiative was re-launched in 1999, only 9(19%) of the 47 countries in the WHO African Region had eliminated MNT (Algeria, Botswana, Cabo Verde, The Gambia, Lesotho, Mauritius, Sao Tome and Principe, Seychelles, and Swaziland). As of November 2016,28 additional countries in the region have eliminated MNT, for a total of 37 (79%) countries, leaving 10 countries yet to achieve MNTE (Angola, Central African Republic (CAR), Chad, Democratic Republic of the Congo (DRC), Ethiopia (Somali Region only), Guinea, Kenya, Mali, Nigeria, South Sudan) (Figure 1). In those 10 countries, the risk of MNT is mainly limited to a few high-risk districts except in countries that are challenged with civil unrest and insecurity (CAR, DRC, Mali, and Nigeria).

 

Tetanus vaccination coverage

 

Immunization programs of all 47 AFR countries recommend three TTCV doses for infants and five appropriately spaced doses for pregnant women and/or WRA, where appropriate [16]. Of the 37 AFR countries that have achieved MNTE, five (14%) include the three WHO-recommended TTCV booster doses for children older than 1 year of age in their immunization schedules (Algeria, Botswana, Mauritius, Seychelles, and South Africa); none of the 10 countries yet to achieve MNTE provide the three WHO-recommended tetanus booster doses in their vaccination schedule [16].

 

The regional average for DTP3/Penta3 coverage has increased from 52% in 2000 to 76% in 2015 overall, though coverage in several countries has not improved during this time period [19, 30]. In 2015, DTP3/Penta3 coverage among countries that had achieved MNTE was 84% compared with 68% among countries that had not yet achieved MNTE (Figure 2). Of the AFR countries that have achieved elimination, 16 (43%) had ≥90% DTP3/Penta3 coverage in 2015 (Table 1). Of the 10 countries that have not achieved MNTE, Kenya is the only country that has ever reached ≥90% DTP3/Penta3 coverage though not in every year since 2010 (Table 2). Ebola-affected countries (Guinea, Liberia, and Sierra Leone) experienced decreases in DTP3/Penta3 coverage rates during and following the outbreak in 2014 and 2015. Over the same time period, Angola and South Sudan had decreases in DTP3/Penta3 coverage, likely due to insecurity. Notably, DTP3/Penta3 coverage has been consistently low (<65%) in Equatorial Guinea which achieved elimination in 2016; such coverage may prove a challenge for maintaining elimination.

 

Both TT2+ and PAB coverage are estimates of tetanus immunity among pregnant women. The percentage of pregnant women covered with TT2+ among all countries in the AFR region increased from 44% in 2000 to 69% in 2015; PAB increased from 62% to77%during the same time period [30]. In countries that have achieved MNTE, the average PAB and TT2+ coverage for 2015 was 86% and 64%, respectively (Figure 2), with ≥ 80% TT2+ or PAB coverage in all but Equatorial Guinea, Madagascar, and Zimbabwe (Table 3). Of the AFR countries that have not yet achieved MNTE, the average PAB and TT2+ coverage in 2015 was 69% and 64%, respectively (Figure 2); among these countries, ≥80% TT2+ or PAB coverage was achieved in Chad, DRC, Ethiopia, Guinea, Kenya, and Mali (Table 4). Guinea and Liberia, which were affected by the 2014 Ebola outbreak, had lower TT2+ coverage in 2014 and 2015 relative to other years, but PAB remained stable. However, Sierra Leone, also affected by the Ebola outbreak, did not have a drop in TT2+ or PAB coverage.TT2+ coverage can underestimate true protection from tetanus, especially in countries with well-established vaccination programs (e.g. Botswana, Cabo Verde, and Comoros), because it excludes women unvaccinated during pregnancy but already protected through previous vaccination or who received one dose in pregnancy and had undocumented previous doses (Table 3) [23, 24].

 

During 1999 to the end of 2016, over 79millionWRAwerevaccinatedwith at least 2 TTCV doses during SIAs in AFR countries, but by the end of 2016 about 5.5 million WRA in AFR countries still need to be reached. Only a limited number of districts are assessed as high-risk in the 10 countries remaining to achieve MNTE (e.g., in DRC only 11 of the 514 health zones are high-risk). The total number of TTSIA phases completed as of April 2016 and number of TT2+ doses provided through SIAs are reported for countries yet to achieve MNTE in Table 5. Most of the required funds are available to support Angola, Chad, DRC, Ethiopia, Guinea, Kenya, and South Sudan to complete all their planned and final TTCV SIAs; these countries are on course to achieve elimination by 2018 [31]. However, most of the funding for TTCV SIAs in CAR, Mali, and Nigeria is still lacking [31].

 

Clean delivery and cord care

 

In addition to vaccination, clean delivery and cord care are essential interventions to prevent and eliminate MNT. The proportion of births delivered by SBAs is a key indicator for monitoring progress towards MNTE. In AFR, the percentage of births attended by SBAs was 54% in 2013 [32]. Of countries that have achieved MNTE, 17 of 37 (46%) have >70% SBA coverage, while 20 (54%) have <70% SBA coverage; Eritrea (34% in 2010), Niger (40% in 2015), Madagascar (44% in 2013), Guinea-Bissau (45% in 2014), and United Republic of Tanzania (49% in 2014) have SBA coverage <50% [27]. Four of these countries with <50% SBA coverage have >80% PAB coverage, while Madagascar has 78% PAB coverage. All countries that have not achieved MNTE have <70% (range 19%-62%) SBA coverage in their last national survey except for DRC, which achieved 80% SBA coverage nationally in 2014 (Table 5). Continued low PAB and SBA coverage could be a risk for sustaining MNTE.

 

Surveillance

 

Sensitive NT surveillance is important for conducting epidemiologic analysis of cases, planning targeted interventions, and evaluating program effectiveness. WHO recommends routine monthly surveillance of NT, including zero reporting, active surveillance, and retrospective record review at major health facilities at least once a year to identify previously unreported NT cases [33]. During 2015, the number of NT cases reported from countries that have not achieved MNTE ranged from 0 in South Sudan to 330 in the DRC, with a respective reported national incidence of 0 to 0.59 NT cases per 1,000 live births (Table 5).However, underreporting of NT surveillance is common, with the efficiency of notification for NT cases globally estimated at less than 11% [2]. Likely causes of NT underreporting include the general occurrence of NT cases in remote and underserved areas,NT deaths occurring in the community without being seen by a health worker, and lack of a robust system of active NT surveillance in most countries.

 

Serosurveys can help monitor progress towards achieving or maintaining MNTE, especially in countries or areas where TT2+ or PAB coverage may not be accurate. In Burundi in 1989, a national serosurvey among women giving birth in the previous year reported 73% PAB coverage and 67% seroprotection [34]. More recently, a national serosurvey in CAR in 1995reported 74% PAB and 89% seroprotection among women giving birth in the past year [35]. In Cambodia in 2012, seroprotection was 88% for WRA overall, while parous women had 83% PAB and 97% seroprotection [23]. PAB coverage can be underestimated due to residual immunity from infant doses in some adult women, booster doses provided outside routine services, misclassification of PAB status due to poor availability of documentation, and recall bias [23]. Serosurveys can help estimate population immunity, which contributes to validation of MNTE, and identify areas at high risk for MNT [36]. Integration of tetanus testing in serosurveys for other antigens (e.g., rubella) using multiplex testing may reduce the cost and resources required [23].

 

Challenges and recommendations for AFR countries that have not yet achieved MNTE

 

A number of challenges exist among the countries that have not yet achieved MNTE. In all the countries that have not yet achieved elimination, weak health systems affect their ability to effectively implement the four MNTE strategies. In most countries, sub-optimal routine immunization is evidenced by low rates of DTP3/Penta3 and TT2+/PAB coverage. The proportion of safe deliveries occurring in health facilities or at home with skilled birth attendants also remains low. Insecurity and unrest in CAR, Nigeria, Mali, and some areas of other countries result in WRAs living in high-risk areas being inaccessible. These countries also have challenges with funding the remaining TTCV SIAs needed to achieve MNTE. Vaccine controversy issues related to targeted vaccination of WRA have also occurred, resulting in varying extents of vaccine hesitancy. In Kenya, the national Conference of Catholic Bishops made public allegations that tetanus vaccine could cause sterility in women, which has delayed the country’s timeline for MNTE [37]. Furthermore, AFR countries face competing priorities both within the EPI program, such as polio eradication (e.g., Nigeria) and measles elimination activities (i.e., throughout AFR), response campaigns to meningitis serogroup A and yellow fever outbreaks, and with other health programs (e.g., Ebola, HIV, TB, malaria).

 

Despite these challenges, MNTE is achievable in the remaining 10 AFR countries if there is strong national commitment, timely availability of resources, high quality micro plans, well implemented activities with monitoring and supervision, active community engagement, and adequate coordination with and implementation of maternal and child health services [31]. The methods to approach the MNTE strategies to reach elimination vary by country.

 

Efforts to strengthen the health care system of AFR countries yet to achieve MNTE could result in increased vaccination of pregnant women through routine services along with improving rates of clean deliveries. Eritrea, Rwanda, South Africa, and Zimbabwe were successful at eliminating MNT through efforts to strengthen the health system, without conducting any TTCV SIAs [31]. To achieve MNTE, Eritrea and Liberia promoted clean deliveries through additional training of traditional birth attendants [38, 39]. Liberia also encouraged facility births with distribution of free kits for mothers, including baby articles and bed nets [39]. Burundi constructed and staffed rural health facilities with trained health workers to provide free health care for mothers and children, in addition to conducting catch-up vaccination during mother and child health weeks [40]. Immunization programs should encourage using every opportunity to provide TTCV to women (e.g., child health days, outreach immunization sessions, periodic intensification of routine immunization, antenatal care visits, family planning visits) to improve coverage. Providing TTCV booster doses in the routine immunization schedule (e.g., in the second year of life with MCV2, or in school) can ensure women are protected, or need fewer booster doses to be protected, by the time they reach reproductive age. Mozambique provides TTCV to WRA during routine EPI sessions and also in secondary schools and workplaces; in addition, children of both sexes are provided TTCV in the first and second grade resulting in continued seroprotection of older children and adolescents [41, 42].

 

Many countries conduct multiple polio and measles SIAs, with many targeting hard-to-reach, inaccessible or previously inaccessible areas (i.e., conflict affected). Integrated campaigns that include TTCV could be an opportunity to reach WRA in high-risk areas. For countries with inaccessible areas or insecurity, innovative approaches such as use of TT-Uniject™ (a heat-stable prefilled injection device) could help reach these populations and improve TTCV coverage for WRA. An evaluation in Mali, where there are a limited number of health workers, showed that community-based volunteers could safely administer TT-Uniject™, communities were accepting of the practice, and previously inaccessible populations were reached [43]. Use of TT-Uniject™ during campaigns would allow unskilled vaccinators to provide vaccine, similar to polio SIAs.

 

India achieved MNTE in 2015 by employing a combination of approaches that may be applicable for some AFR countries. India faced similar challenges to the AFR region including a history of unsafe birth practices during home deliveries and suboptimal TTCV coverage [44]. Some of the approaches used in India to achieve MNTE included addition of TTCV booster doses to the childhood immunization schedule, immunization of pregnant women during antenatal care visits, implementation of SIAs in high-risk areas, and extension of outreach services to include vaccination of children, adolescent, and pregnant women with TTCV. India also promoted institutional deliveries through the provision of conditional cash transfers, communication with communities on clean cord care practices, and distribution of clean delivery kits to SBAs [44, 45].

 

As mentioned above, sensitive NT surveillance is a challenge for countries trying to achieve MNTE. Developing standardized NT surveillance guidelines with performance indicators similar to those used for acute flaccid paralysis (AFP for polio) and measles-rubella (MR) surveillance are needed to improve NT surveillance; such guidelines and indictors already exist for the Region of the Americas and could be adapted to other regions. Active surveillance for NT cases has been successfully integratedinto existing active case-based surveillance activities for AFP and MRin many countries, resulting in more robust NT reporting. For example in Nepal, NT surveillance was integrated into the AFP surveillance system, which uses a network of surveillance medical officers reporting weekly from 413 sentinel surveillance sites (10% of government health facilities), and investigating suspected NT cases using a standard case-investigation form [46]. Since many neonatal deaths occur at home, it is important to supplement health facility-based surveillance with community based surveillance. In addition, sensitivity of NT surveillance may be improved through investigation of neonatal deaths reported through vital registration and reporting [31].

 

Sustaining elimination

 

Because tetanus cannot be eradicated from the environment, countries need to have a plan for sustaining MNTE. Attention to MNT will likely decrease after elimination along with resources. However, efforts to ensure clean deliveries, maintain high immunization coverage of pregnant women, and strengthen NT surveillance should be continued through integration with routine programs. Countries with weak health systems that achieved elimination through SIAs need to have employed additional strategies for reaching women beyond routine services, which may include continued SIAs in high risk areas and outreach activities during child health days or antenatal care, to ensure population immunity does not lapse after MNTE validation [7].

 

Providing TTCV booster doses during the second year of life, childhood, and adolescence in the routine schedule will help ensure individuals of all ages and both sexes are adequately protected without relying on SIAs [3]. As school attendance has increased in the African region, school-based immunizations platforms are increasingly attractive platforms for administering booster doses during childhood and adolescence. In 2012, 24% of AFR countries reported providing vaccinations in school [47]. Opportunities to provide TTCV boosters increasingly exist as AFR countries, many with funding assistance from GAVI, the Vaccine Alliance, introduce vaccinations given beyond the first year of life, including a second dose of measles containing vaccine (MCV2) in the second year of life (2YL) and human papillomavirus vaccine in early adolescence [48]. As of September 2016, 25(53%) AFR countries provided MCV2, most during the 2YL [16]. Additionally, booster doses would address tetanus immunity gaps in older children and adult men in the region [42, 49]. Attention was brought to the seriousness of this issue after cases of tetanus were reported following voluntary medical male circumcision in Eastern and Southern African countries [49, 50]. When countries develop plans to maintain MNTE, it is important to include booster doses for both sexes to improve equity, ensure long-term protection and decrease the burden of tetanus in all ages.

 

Most countries in the African meningitis belt have or will introduce the meningococcal serogroup A polysaccharide TT-conjugate vaccine (MenAfriVac) by conducting SIAs targeting persons aged1–29 years, followed by introduction into the routine immunization schedule during the first or second year of life [16]. Results from a serosurvey conducted in Mali before and after the MenAfriVac campaign showed significant increases in tetanus immunity 2 years after the SIA [51]. A 25% reduction in NT cases was observed after MenAfriVac SIAs in 5 African countries, compared with before the SIA [52]. Therefore, MenAfriVac introduction in AFR countries in the meningitis belt could help boost tetanus immunity in those populations and support MNTE.

 

Effective NT surveillance, including sensitive and timely identification of NT cases, targeted implementation of control strategies, and effective monitoring and evaluation of the impact of these strategies, will be critical to sustaining MNTE. In addition to improving NT surveillance as mentioned above, annual reviews of data should be done to identify districts that could be at high-risk for MNT resurgence and need to implement additional control strategies to sustain MNTE [31]. In countries that have achieved MNTE, tetanus serosurveys of tetanus immunity in countries that have achieved MNTE can help supplement district level data reviews by identifying immunity gaps, which can provide evidence for the need for booster doses, including optimal schedules, and the need for targeted vaccination [31, 36].

 

 

Though MNTE was not achieved in AFR by the target date of 2015, significant progress has been made in the region where 37(79%) of 47 countries have achieved elimination as of November 2016. Table 6 summarizes the key findings of the MNTE strategies in the AFR region. In 2015, PAB and TT2+ coverage increased to 77% and 69% compared to 62% and 44% in 2000, respectively. Nevertheless, the region has 10 (56%) of the 18 countries worldwide that are yet to achieve MNTE. The majority of these countries are challenged with insecurity, weak health systems, competing priorities, and/or insufficient funding. In countries with insecurity, use of pre-filled injection devices, and integration of TTCV SIAs with polio and/or measles vaccination SIAs, or post-conflict campaigns, could help ensure tetanus protection among WRA in high-risk areas. To achieve and maintain MNTE, programs should use every available opportunity to provide TTCV to pregnant women, including in antenatal clinics, outreach, and during child health days. Providing the WHO-recommended TTCV booster doses to both sexes, e.g., in the 2YL, childhood (4-7 years), and adolescence (9–15 years), would help ensure women are protected before pregnancy and reduce the tetanus burden across the whole population. Case-based NT surveillance could be strengthened by development of standardized performance indicators and integration with active surveillance for AFP and MR. Countries that have achieved MNTE should develop plans to maintain elimination, including efforts to ensure high-quality NT surveillance and high tetanus immunity among WRA. Serosurveys may provide important information on tetanus population immunity for countries that have yet to achieve, as well as those that have already achieved MNTE.

 

 

The authors declare no competing interest.

 

 

Ridpath A designed the study, review the literature, summarized the data, and prepared the manuscript. Scobie H, Tohme R, contributed to the design, interpretation of the results, and thoroughly reviewed and provided comments to the manuscript. Shibeshi M, Yakubu A, Raza A, Zulu F, Masresha B contributed to acquisition of the data, interpretation of the results, thoroughly reviewed and provided comments to the manuscript. Each author has given final approval of the version to be published. All the authors have read and agreed to the final manuscript.

 

 

The authors would like to Acknowledge Jennifer Knapp PhD, MPH from the Centers for Disease Control and surveillance for her assistance in developing Figure 1. Disclaimer: Use of trade names is for identification only and does not imply endorsement by the Public Health Service or by the U.S. Department of Health and Human Services. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention.

 

 

Table 1: WHO-UNICEF coverage estimates for the third dose of Diphtheria, Tetanus, and Pertussis Vaccine (DTP3/Penta3) among children aged <12 months in countries that have achieved Maternal Neonatal Tetanus Elimination — WHO Africa Region 2000, 2005, and 2010-2015a

Table 2: WHO-UNICEF coverage estimates for the third Dose of Diphtheria, Tetanus, and Pertussis Vaccine (DTP3/Penta3) among children aged <12 months in countries that have not achieved Maternal Neonatal Tetanus Elimination — WHO Africa Region 2000, 2005, and 2010-2015a

Table 3: tetanus coverage^a,b among pregnant women in countries that have achieved Maternal and Neonatal Tetanus Elimination — WHO African Region, 2000, 2005, and 2010–2015

Table 4: tetanus coverage^a,b among pregnant women in countries that have not achieved Maternal and Neonatal Tetanus Elimination — WHO African Region, 2000, 2005, and 2010–2015

Table 5: number of TT supplementary immunization activities and years conducted, number of TT2+ doses provided through SIAs, current skilled birth attendant coverage, and reported neonatal tetanus cases and incidence in countries that have not achieved Maternal and Neonatal Tetanus Elimination - African Region

Table 6: summary of current key findings on the status of Maternal and Neonatal Tetanus Elimination (MNTE) Strategies in the WHO African Region

Figure 1: Maternal Neonatal Tetanus Elimination Status- WHO African Region, 2016

Figure 2: average tetanus vaccination coverage of WHO African region countries by maternal and neonatal tetanus elimination status during 2000, 2005, 2010 and 2015

 

 

1. Roper MH, Vandelaer JH, Gasse FL. Maternal and neonatal tetanus. Lancet. 2007 Dec 8;370(9603):1947-59. PubMed | Google Scholar


2. Khan R, Vandelaer J, Yakubu A, Raza AA, Zulu F. Maternal and neonatal tetanus elimination: from protecting women and newborns to protecting all. Int J Womens Health. 2015;7:171-80. PubMed | Google Scholar


3. World Health Organization. Tetanus vaccines: WHO Position Paper - February 2017. Wkly Epidemiol Rec. 2017 Feb 10; 92(6):53-76. PubMed | Google Scholar


4. Roper M, Wassilak S, Tiwari T, Orenstein W. Tetanus Toxoid. In: Plotkin S, Orenstein W, editors. Vaccines. 6. Philadelphia: W.B. Saunders; 2013. p. 746-72.


5. Blencowe H, Lawn J, Vandelaer J, Roper M, Cousens S. Tetanus toxoid immunization to reduce mortality from neonatal tetanus. Int J Epidemiol. 2010 Apr;39 Suppl 1:i102-9. PubMed | Google Scholar


6. Blencowe H, Cousens S, Mullany LC, Lee AC, Kerber K, Wall S et al. Clean birth and postnatal care practices to reduce neonatal deaths from sepsis and tetanus: a systematic review and Delphi estimation of mortality effect. BMC Public Health. 2011 Apr 13;11 Suppl 3:S11. PubMed | Google Scholar


7. United Nations Children Fund, United Nations Population Fund, World Health Organization. Achieving and sustaining Maternal and Neonatal Tetanus Elimination: Strategic Plan 2012-2015, Geneva, Switzerland: WHO; 2012. Accessed 2016 September 18.


8. Khan AA, Zahidie A, Rabbani F. Interventions to reduce neonatal mortality from neonatal tetanus in low and middle income countries-a systematic review. BMC Public Health. 2013 Apr 09;13:322. PubMed | Google Scholar


9. Darmstadt GL, Bhutta ZA, Cousens S, Adam T, Walker N, de Bernis L et al. Evidence-based, cost-effective interventions: how many newborn babies can we save? Lancet. 2005 Mar 12-18;365(9463):977-88. PubMed | Google Scholar


10. Galazka A, Birmingham M, Kurian M, Gasse F. Tetanus. In: Murray C, Lopez A, Mathers C, editors. The Global Epidemiology of Infectious Diseases Geneva: World Health Organization; 2004. p. 151–99.


11. Vandelaer J, Birmingham M, Gasse F, Kurian M, Shaw C, Garnier S. Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative. Vaccine. 2003 Jul 28;21(24):3442-5. PubMed | Google Scholar


12. United Nations Children Fund, World Health Organization, United Nations Population Fund. Maternal and Neontal Tetanus Elimination by 2005: Strategies for achieving and maintaining elimintion: UNICEF; 2000. Accessed 2016 October 26.


13. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE et al. Global, regional and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015 Jan 31;385(9966):430-40. PubMed | Google Scholar


14. World Health Organization. Maternal and Neonatal Tetanus (MNT) elimination: Progress towards global MNT elimination. 2016. Updated November 9, 2016; Cited 2016 December 18.


15. World Health Organization. Global Vaccine Action Plan 2011-2020. 2013. Accessed 2016 December 18.


16. World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2016 global summary. 2016. Updated July 15, 2016; Accessed 2016 September 29.


17. World Health Organization. Data, statistics and graphics 2016. Updated December 1, 2016; Accessed 2016 December 16.


18. World Health Organization. Tetanus (neonatal) reported cases 2016. Updated December 1, 2016; Accessed 2016 November 11.


19. World Health Organization. WHO-UNICEF estimates of DTP3 coverage 2016 . Updated July 15, 2016. cited 2016 September 18.


20. World Health Organization. World Health Organization. WHO-UNICEF estimates of PAB coverage 2016. Updated July 15, 2016; Accessed 2016 September 16.


21. World Health Organization. Second and subsequent doses of tetanus toxoid 2016. Updated December 1, 2016; Accessed 2016 September 18. Google Scholar


22. Griffiths UK, Wolfson LJ, Quddus A, Younus M, Hafiz RA. Incremental cost-effectiveness of supplementary immunization activities to prevent neonatal tetanus in Pakistan. Bull World Health Organ. 2004 Sep;82(9):643-51. PubMed | Google Scholar


23. Scobie HM, Mao B, Buth S, Wannemuehler KA, Sorensen C, Kannarath C et al. Tetanus Immunity among Women Aged 15 to 39 Years in Cambodia: a National Population-Based Serosurvey, 2012. Clin Vaccine Immunol. 2016 Jul;23(7):546-54. PubMed | Google Scholar


24. World Health Organization. Protection-at-birth (PAB) method, Tunisia. Wkly Epidemiol Rec. 2000 Jun 23;75(25):203-6. PubMed | Google Scholar


25. United Nations Population Division. World Population Prospects: The 2015 Revision, DVD Edition 2015. Accessed 2016 December 18. Google Scholar


26. World Health Organization. Maternal and Neonatal Tetanus (MNT) elimination: Supplementary Immunization Activities MNTE 2016. Updated April 21, 2016; Accessed 2016 November 5.


27. United Nations Children Fund. Skilled Attendance. 2016. Updated February 2016; Accessed 2016 September 18.


28. World Health Organization. Maternal and Neonatal Tetanus (MNT) related publications and useful links 2016. Updated December 1, 2013; Accessed 2016 December 18. Google Scholar


29. World Health Organization. SAGE meeting of October 2016. 2016. Accessed 2016 December 15. Google Scholar


30. World Health Organization. Global and regional immunization profile: African Region. 2016. Updated November 18, 2016; Accessed 2016 December 19. Google Scholar


31. World Health Organization. Report of the SAGE Working Group on Maternal and Neonatal Tetanus Elimination and Broader Tetanus Prevention. 2016. Accessed 2016 December 15. Google Scholar


32. World Health Organization. Health service coverage data by WHO region. 2016. Updated May 18, 2016; Accessed 2016 November 3. PubMed | Google Scholar


33. World Health Organization. WHO-recommended standards for surveillance of selected vaccine-preventable diseases. 2003. Updated July 2008; Accessed 2016 December 18. Google Scholar


34. World Health Organization. Expanded programme on immunization-estimating tetanus protection of women by serosurvey. Wkly Epidemiol Rec. 1996 Apr 19;71(16):117-24. PubMed | Google Scholar


35. Deming MS, Roungou JB, Kristiansen M, Heron I, Yango A, Guenengafo A et al. Tetanus toxoid coverage as an indicator of serological protection against neonatal tetanus. Bull World Health Organ. 2002;80(9):696-703. PubMed | Google Scholar


36. Cutts FT, Hanson M. Seroepidemiology: an underused tool for designing and monitoring vaccination programmes in low- and middle-income countries. Trop Med Int Health. 2016 Sep;21(9):1086-98. PubMed | Google Scholar


37. BBC. Kenya Catholic Church Tetanus Vaccine Fears 'unfounded'. 2014 (updated October 13, 2014; accessed 2016 December 18). Google Scholar


38. World Health Organization. Assessment of neonatal tetanus elimination in Eritrea. Wkly Epidemiol Rec. 2004 Jun 11;79(24):222-7. PubMed | Google Scholar


39. World Health Organization. Validation of maternal and neonatal tetanus elimination in Liberia, 2011. Wkly Epidemiol Rec. 2012 May 4;87(18):169-76. PubMed | Google Scholar


40. World Health Organization. Validation of neonatal tetanus elimination in Burundi and the Comoros by a lot quality assurance cluster sampling survey, 1 October 2008- 30 September 2009. Wkly Epidemiol Rec. 2011 Jul 8;86(28):289-99. PubMed | Google Scholar


41. World Health Organization. Validation of elimination: maternal and neonatal tetanus in Mozambique, 2010. Wkly Epidemiol Rec. 2011 Oct 28;86(44):481-8. PubMed | Google Scholar


42. Scobie HM, Patel M, Martin D, Mkocha H, Njenga SM, Odiere MR, et al. Tetanus Immunity Gaps in Children 5-14 Years and Men ≥ 15 Years of Age Revealed by Integrated Disease Serosurveillance in Kenya, Tanzania, and Mozambique. Am J Trop Med Hyg. 2017 Feb 8;96(2):415-420. PubMed | Google Scholar


43. D’Alois L SB, Millogo J, Diarra S, Plowman BA, Steinglass R. Impact of Delivery Technologies on Increased Access. TT-Uniject Report Mali. 2004. Updated March, 2004; Accessed 2016 December 18.


44. World Health Organization. Maternal and neonatal tetanus elimination: validation survey in 4 States and 2 union territories in India, May 2015. Wkly Epidemiol Rec. 2015 Oct 30;90(44):589-608. PubMed | Google Scholar


45. World Health Organization. Maternal and neonatal tetanus elimination: validation survey in 4 States in India, April 2013. Wkly Epidemiol Rec. 2014 May 2;89(18):177-88. PubMed | Google Scholar


46. Vandelaer J, Partridge J, Suvedi BK. Process of neonatal tetanus elimination in Nepal. J Public Health (Oxf). 2009 Dec;31(4):561-5. PubMed | Google Scholar


47. Vandelaer J, Olaniran M. Using a school-based approach to deliver immunization-global update. Vaccine. 2015 Jan 29;33(5):719-25. PubMed | Google Scholar


48. Global Vaccine Alliance Initiative. New and underused vaccines support GAVI; 2016. Accessed 2016 December 20.


49. Dalal S, Samuelson J, Reed J, Yakubu A, Ncube B, Baggaley R. Tetanus disease and deaths in men reveal need for vaccination. Bull World Health Organ. 2016 Aug 1;94(8):613-21. PubMed | Google Scholar


50. Grund JM, Toledo C, Davis SM, Ridzon R, Moturi E, Scobie H, et al. Notes from the Field: Tetanus Cases After Voluntary Medical Male Circumcision for HIV Prevention--Eastern and Southern Africa, 2012-2015. Morb Mortal Wkly Rep. 2016 Jan 22;65(2):36-7. PubMed | Google Scholar


51. Basta NE, Borrow R, Berthe A, Onwuchekwa U, Dembele AT, Almond R et al. Higher Tetanus Toxoid Immunity 2 Years After PsA-TT Introduction in Mali. Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S578-85. PubMed | Google Scholar


52. Borrow R, Tang Y, Yakubu A, Kulkarni PS, LaForce FM. MenAfriVac as an Antitetanus Vaccine. Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S570-7. PubMed | Google Scholar